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Studies on the metabolism of aldosterone in chronic renal
failure and anephric man. Studies on anephric man and patients
with chronic renal failure were undertaken to investigate the role
of the kidneys in the control of aldosterone secretion. Volume
depletion produced by isonatremic, isokalemic volume deple-
tion did not result in increased plasma aldosterone concentra-
tions in anephric man. ACTH and angiotensin II infusion and
postural change also failed to stimulate aldosterone production
in these subjects. Patients with chronic renal failure, but with
kidneys and receiving hemodialysis, also in general failed to
respond to ACTH or to postural change. Volume depletion,
upright posture and other direct stimuli of aldosterone secretion
did not have a significant effect in anephric patients. Since most
patients with chronic renal failure on hemodialysis also demon-
strated blunted responses in contrast to those not on hemodialysis,
some aspect of the dialysis process itself may have interfered with
the adrenal response to acute stimulation. From these studies, it
was not possible to delineate whether the renin-angiotensin
system plays a permissive or dominant role in regulation of
aldosterone secretion in man.
Etude du métabolisme de l'aldostérone an cours de l'insuffisance
rénale chronique et chez l'bomme anéphrique. Des etudes chez
l'homme anephrique et chez des malades atteints d'insuffisance
rénale chronique ont été entreprises afin d'apprécier le role des
reins dans le contrôle de Ia secretion d'aldostérone. La diminu-
tion du volume extracellulaire produite par une déplétion iso-
natrémique et isokaliémique n'a pas eu pour consequence une
augmentation de Ia concentration plasmatique d'aldostérone
chez l'homme anéphrique. L'ACTH Ia perfusion d'angioten-
sine II et les modifications posturalés n'ont pas, non plus,
stimulé Ia production d'aldostérone chez ces sujets. Des malades
atteints d'insuffisance rénale chronique, mais pourvus de leurs
reins et soumis a l'hémodialyse, n'ont pas, en general, répondu
a I'ACTH ou aux modifications posturales. La diminution du
volume extracellulaire, Ia position debout et d'autres stimuli
directs de Ia secretion d'aldostérone n'ont pas eu d'effet signifi-
catif chez les malades anéphriques. Du fait que Ia plupart des
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malades atteints d'insuffisance rénale le chronique et soumis a
l'hémodialyse ont eu aussi des réponses attCnuCes a ces stimuli,
a Ia difference des sujets non soumis a l'hCmodialyse, il apparait
qu'un aspect du processus de dialyse lui-même peut avoir inter-
fCrC avec Ia réponse surrénalienne a Ia stimulation aiguC. II n'a
pas été possible, a partir de ce travail, de determiner Ic role
permissif ou dominant du système rénine angiotensine sur Ia
secretion d'aldostérone chez l'homme.
Since 1960 considerable attention has been directed to
the role of the kidney in the control of aldosterone secre-
tion. Early experiments showed that nephrectomy of the
sodium-depleted hypophysectomized dog resulted in a fall
in the rate of aldosterone secretion [1, 2] and that absence
of the kidney prevented the rise in aldosterone secretion
usually seen in response to hemorrhage [1]. Subsequently,
it has been established that the renin-angiotensin system
plays a major role in the control of aldosterone secretion
[3—6]. Administration of angiotensin II was shown to in-
crease aldosterone secretion [7, 8] by a direct effect on the
adrenal cortex [9]. Renin administration was also shown
to stimulate aldosterone secretion in man [10].
Experiments have shown considerable differences be-
tween species in the part played by the renin-angiotensin
system in the aldosterone response to sodium depletion.
In contrast to findings in the rat [11, 12], available evidence
in the dog and sheep would suggest that the renin-angio-
tensin system is necessary for the aldosterone response to
sodium depletion [1, 4, 6]. Although in man plasma renin
concentration [131 and activity [14], angiotensin II levels
[IS], and plasma aldosterone concentration [16] and aldo-
sterone secretion rate rise during sodium restriction, the
precise role that the kidney plays in the control of aldo-
sterone secretion in man is not known.
The present studies were designed to examine the aldo-
sterone response to volume depletion in anephric man and
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to further the understanding of the metabolic problems of
these patients. Isonatremic, isokalemic volume depletion
was used as the stimulus to eliminate the direct effect of
cl'anges in plasma sodium and potassium concentrations
on aldosterone secretion. Dexamethasone was used to sup-
press adrenocorticotropin (ACTH) secretion to prevent
changes in ACTH levels from influencing aldosterone secre-
tion. As plasma aldosterone concentrations failed to rise
in these experiments, the effect of administration of angio-
tensin II and ACTH, two direct-acting stimuli, was in-
vestigated in these patients, and the aldosterone response to
ACTH and postural changes was examined in both un-
dialyzed and dialyzed subjects with chronic renal failure.
From these latter experiments, we hoped to establish
whether the failure of aldosterone concentration to rise in
response to volume depletion was due to 1) the lack of
kidneys, 2) a defect in aldosterone production from the
adrenal, perhaps due to metabolic effects of uremia, or
3) effects of intermittent hemodialysis.
Methods
Patient selection. This study consists of an evaluation of
aldosterone metabolism during 37 experiments in 26 pa-
tients with chronic renal failure, i.e., creatinine clearance
values <10 mI/mm for at least four months. The twenty-
six patients were selected from a large group of patients
with chronic renal failure on the basis of their willingness to
participate in the project, the relative stability of their
clinical state and their freedom from other diseases at the
time of study. Eleven of these patients were anephric in
preparation for renal transplantation (dialysis time =1 to
15 months), hereafter referred to as AN. Six patients had
undergone no hemodialysis prior to study (NE), and nine
patients had been on hemodialysis without nephrectomy
for periods ranging from I to 28 months (NEH). Three
patients were studied both prior to hemodialysis and after
undergoing hemodialysis for one to twelve months. The
age, sex, duration of chronic renal failure, and duration of
hemodialysis are detailed in Table I. The duration of
hemodialysis of patients with kidneys (9.2 months) was
similar to that without (8.3 months). In general, 300 mg
of heparin was administered weekly to patients undergoing
hemodialysis. This usually consisted of a 100 mg infusion
over an 8-hour period three times weekly. The day of
study was the day after dialysis. All patients were studied
at the Clinical Research Center of the Peter Bent Brigham
Hospital.
Protocols: 1. Aldosterone response to acute volume deple-
tion in anephric man. Four anephric individuals (AN) were
studied five times during acute hemodialysis-induced iso-
natremic, isokalemic volume depletion. Study was accom-
plished by adjusting the dialysis bath fluid to maintain a
constant plasma sodium and potassium concentration
under conditions of ultrafiltration dialysis. A number of
aldosterone determinations were made during this period.
The basic protocol was as follows: the patients were
dialyzed a day before the study in order to assure an
optimum metabolic state during the study period. They
were maintained supine throughout the study except for
sitting 5 minutes for blood pressure recording just after
baseline and post-hemodialysis samples were obtained. All
of the subjects except for D-2 were maintained on dexa-
methasone therapy, 1.0 mg every six hours for the day
prior to study and the day of study. All other medications
were unchanged. Samples for determining the values of
the following were taken prior to dialysis, at the completion
of dialysis, and 3 and 24 hours after dialysis: aldosterone,
cortisol, corticosterone, electrolytes, blood urea nitrogen
(BUN), creatinine, hematocrit and renin. The object of
this study was to effect an acute volume depletion in the
anephric individual equivalent to a loss of 2 kg in body
weight over the period of dialysis. The dialysis was termi-
nated when this occurred or if the patient became hypo-
tensive. In no individual did the dialysis run longer than
six hours. The metabolic clearance rate of aldosterone and
the 1311-albumin plasma volumes were determined before
and at the completion of dialysis. The volume of blood
removed for analysis was replaced quantitatively by cross-
matched blood.
2. Effect of postural change in patients with chronic renal
failure and in anephric man. Three groups of patients were
studied on this protocol, four subjects who had been neph-
rectomized (AN) and six subjects with chronic renal failure,
three of whom (NEH) had been treated with hemodialysis
and three (NE) who had not. One anephric individual (B)
was studied while on dexamethasone therapy, 1 mg q.i.d.
on the day prior to study and the day of the study. Plasma
aldosterone, corticosterone, cortisol, blood gas and elec-
trolyte concentrations were determined at 0800 and 1500.
All patients were kept supine from 2330 until 0800 and
remained upiight and walking from 0800 until 1100. They
then were allowed to sit or walk as they pleased but were
not allowed to lie down until 2330. Plasma samples were
drawn for determination of electrolyte, aldosterone, corti-
sol and corticosterone concentrations at 0800 and again
at the completion of their forced upright activity at 1100.
3. Response to angiotensin II infusion in patients with
chronic renal failure. Five studies were performed on two
anephric individuals (AN) to determine aldosterone, cortisol
and corticosterone response to angiotensin II infusion. In
the study involving the pressor infusion, the protocol was
as follows: patients were studied the day following hemo-
dialysis and were maintained supine throughout the study.
Angiotensin II was diluted in 500 ml of 5% glucose and
water to make the final concentration 0.3 jsg of angio-
tensin per ml. Infusion was started at the rate of 0.2 ml!
minute and the dose was gradually increased every 10 min-
utes until a sustained increase of diastolic blood pressure of
20 mm Hg was obtained. The dose was then maintained
for 6 hours. Blood samples for determining the concentra-
tions of aldosterone, electrolytes, BUN, creatinine, cortisol
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Table 1. Summary of patient history and experiments
Patient Age
years
Sex Duration of
renal failure
months
Kidneys Duration of
hemodialysis
months
Studies
A 17 M 6 — 1 Corticotropin infusion (A)
B 15 M 21
24
—
—
4
7
Posture
Corticotropin
(B-I)
(B-2)
C 28 M 21
23
24
—
—
—
12
14
15
Volume depletion
Volume depletion
Corticotropin
(C-i)
(C-2)
(C-3)
D
E
28
50
M
M
40
41
41
44
44
12
24
—
—
—
—
—
+
+
3
4
4
7
7
0
12
Corticotropin
Volume depletion
Angiotensin-pressor
Angiotensin-pressor
Angiotensin-subpressor
Corticotropin
Corticotropin
(D-1)
(D-2)
(D-3)
(D-4)
(D-5)
(E-1)
(E-2)
F 36 M 26 + 2 Corticotropin (F)0 62 M 14 + 2 Corticotropin (G)
H 46 M 5 + 1 Corticotropin (H)
I 28 F 27 + 0 Corticotropin (1)
J 19 M 12 + 0 Corticotropin (J)
K 45 M 17
17
—
—
13
13
Angiotensin-pressor
Angiotensin-subpressor
(K-i)
(K-2)
L 38 F 21 — 15 Posture (L)
M 28 F 36 — 4 Posture (M)
N 26 M 60 — 8 Posture (N)0 41 M 24 — 15 Posture (0)
P 24 M 14 + 0 Posture (P)
Q 62 M 5 + 0 Posture (Q)
R 36 M 4 + 0 Posture (R)
S 35 M 9 — 3 Volume depletion (S)
T 39 M 20 — 8 Volume depletion (T)
U 22 M 28 + 26 Posture (U)
V 28 M 12 + 10 Posture (V)
W 60 M 34 + 28 Posture (W)
X 15 F 4
5
+
+
0
1
Corticotropin
Corticotropin
(X-l)
(X-2)
Y 57 M 16
17
+
+
0
1
Corticotropin
Corticotropin
(Y-1)
(Y-2)
Z 55 F 3 + 0 Corticotropin (Z)
and corticosterone were drawn before and at the completion
of the infusion. After a wait of five days and again the
day following hemodialysis, the patients were retested with
a similar protocol, only this time the angiotensin infusion
was maintained at a level below that known to cause an
elevation in blood pressure. Blood samples were drawn at
similar times and the infusion was again allowed to run
for a total of 6 hours. Throughout both studies, the blood
pressure was monitored every 15 minutes with a sphygmo-
manometer.
4. Response to administration of ACTH in patients with
chronic renal failure and in anephric man. This phase of the
protocol involved sixteen studies: four individuals were
anephric (AN), six individuals had been on hemodialysis
but had not been nephrectomized (NEH) and six individuals
with chronic renal failure were studied prior to hemodia-
lysis (NE). The patients remained supine throughout the
study. Those who were on hemodialysis were studied the
day after hemodialysis. All were given 40 units of ACTH
in 250 ml of 5% dextrose and water from 0800 to 1300 in
patients X-1, X-2, Y-1, Y-2, and Z and to 1600 in the rest
except for patient D. Blood samples were drawn before
starting and at the completion of the infusion for the deter-
mination of electrolyte, creatinine, aldosterone, cortisol and
corticosterone values. One patient (D) had a continuous
24 hour (1000 to 1000) infusion consisting of 80 units of
ACTH in 1000 ml of 5% dextrose and water. Samples
were drawn approximately every three of four hours for
determination of plasma aldosterone, corticosterone, corti-
sol and electrolyte concentrations. Creatinine and hemato-
crit values were determined before and at the completion
of the infusion.
Laboratory procedures. Flame photometry was used to
determine the plasma concentrations of sodium and potas-
sium. The plasma volumes were determined by radio-
active dilution principle, using albumin labeled with 1311.
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The metabolic clearance rate of aldosterone was deter-
mined by continuous infusion of aldosterone as described
by Tait et a! [17].
The rest of the routine determinations were performed
in the hospital's clinical chemistry laboratory.
Plasma samples for steroid hormone and renin measure-
ments were deep-frozen and transported, frozen, by air to
the Howard Florey Laboratories. Plasma aldosterone,
cortisol and corticosterone concentrations were determined
by the double isotope derivative dilution procedure of
Coghlan and Scoggins [18] and plasma renin concentration
by an enzyme kinetic procedure [19]. Plasma steroids in
subjects U through Z were measured by the displacement
analysis technique of Underwood and Williams [20]. Some
samples were run both by a double isotope derivative
method and displacement analysis with excellent agree-
ment, as previously reported [201.
Results
Aldosterone response to acute volume depletion in anephric
man. The detailed results of this study appear in Table 2
and Fig. 1. Results are presented for samples taken before,
during and after hemodialysis. In all patients, hemodialysis
resulted in a 2-kg loss in body weight, but this volume
depletion did not result in any increase in plasma aldo-
sterone concentration, all values being in the lower part
of the normal range. The metabolic clearance rate of aldo-
sterone showed no consistent change over the period of
dialysis so aldosterone secretion presumably remained low
throughout the period of investigation. While the study
Table 2. Metabolic data on five anephric patients during isonatremic, isokalemic volume depletion
Pa-
tient
Hemo-
dialysis
hour
Timea
hour
BUN
mg/100 ml
P,
mg/100 ml
pH Hert
%
Plasma
volume
ml
BP
(sitting)
mm Hg
Aldo-
sterone
MCR
liters/day
Medication
C-i 1100
1515
1100
1515
0700
49
—
39
11.6
—
11.0
7.37
7.35
26.0
29.5
26.5
4794
3999
—
110/75
90/60
—
2320
2310
—
Dexamethasone (Decadron),
multivitamins, folic acid,
lincomycin hydrochloride
monohydrate (Lincocin),
heparin
C-2 0730
1200
0700
1200
0700
57
—
51
10.1
—
8.9
7.47
—
—
25.0
—
28.0
—
—
—
116/85
85/55
—
2490
1690
—
Dexamethasone, multivitamins,
folic acid, diphenylhydantoin
sodium (Dilantin), chloral
hydrate, heparin
D-2 1155
1445
0730
43
43
—
9.6
10.1
—
7.43
7.40
—
34.0
28.0
—
3833
3644
—
118/72
95/65
—
2830
3360
—
Folic acid, diphenyihydantoin,
lincomycin hydrochloride,
warfarin sodium (Coumadin),
heparin
S 1055
1505
1000
1505
0700
33
20
34
7.1
4.8
5.7
7.42
7.52
—
33.0
33.0
—
3247
3033
—
124/68
102/60
—
2468
2286
—
Methyldopa (Aldomet), digoxin,
diphenhydramine hydrochloride
(Benadryl), chlordiazepoxide
HCI (Librium), ampicillin,
heparin, dexamethasone
T 1105
1355
1000
1500
0720
38
40
—
7.5
7.3
—
7.50
7.47
—
25.0
—
—
—
—
—
122/84
100/70
—
1610
—
—
Hydralazine, oxacillin, folic acid,
heparin, dexamethasone
a Samples prior to dialysis, at end of dialysis and following morning.
7.0
6.0
g 5.0
A fl
Plasma K Plasma
aldosterone
Plasma Na
150
140
E 130
Body weight
-
0
ao -l
—2
10
—3
Plasma renin
concentration
Before After 24 hr
dialysis
Before After 24 hr
dialysis
Fig. 1. Grouped results for isonatremic, isokalemic volume deple-
tion in 5 anephric subjects. Predialysis values and those im-
mediately and 24 hours after dialysis are shown.
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was designed to produce isonatremic, isokalemic volume
depletion, in three cases plasma potassium concentrations
changed. Dexamethasone administration effectively sup-
pressed ACTH as evidenced by the plasma cortisol and
corticosterone concentrations in two of the four patients
in which it was used. In one of the other studies (S), the
patient suffered an acute pyrogenic reaction and cortisol
concentrations were high. The reason for the high cortisol
concentrations in the face of dexamethasone suppression
in the other study is not known. In the three experiments in
which plasma renin concentration was measured, they were
detectable but unresponsive to volume depletion (Fig. 1).
Hypotension occurred as a result of volume depletion in
all subjects when seated. This was in contrast to our ex-
perience with over one hundred subjects with normal renal
function who have had a similar dialysis-induced 2 kg
weight loss over a corresponding time interval. Only one
of these has developed hypotension.
Effect of postural change on plasma aidosterone, cortisol
and corticosterone concentrations. The experimental results
of ten studies are shown in Fig. 2. None of the patients was
edematous. Only two subjects showed a significant rise in
plasma aldosterone concentration. Neither had received
heparin therapy. In the five anephric subjects, plasma aldo-
sterone concentrations were very low and did not increase
after three hours in the upright posture. The aldosterone
concentrations of individuals who were reclining were very
low even though plasma potassium concentrations were in
the upper range of normal for three subjects and markedly
elevated in the fourth. In contrast, in two of the three sub-
jects with chronic renal failure (NE), a rise in plasma aldos-
terone concentration was obtained. However, in all three
patients with chronic renal failure on hemodialysis (NEH),
Supine Erect
Aldosterone
Fig. 2. Effect ofpostural change on plasma aldosterone, cortisol
and corticosterone concentrations in anephric patients on chronic
hemodialysis and in patients with chronic renal failure who had
or had not been dialyzed. (.)=anephric, (0) = no hemodialysis,
(A) = hemodialysis.
the results were similar to those seen in the anephric subjects
(AN). In four nephric subjects (two NE and two NEH), the
upright posture produced a significant 50% increase in
renin activity, yet only in the subjects not on hemodialysis
was this accompanied by a rise in plasma aldosterone con-
centration.
Plasma cortisol and corticosterone concentrations were
similar in all patients and, as expected, did not show any
consistent pattern of response, although there was a trend
for the values of individuals in an upright position to be
greater than the ones of those in a supine position. With
one exception (patient N) all values were within the normal
range [18, 20].
Aldosterone, corticosterone and cortisol response to angio-
tensin 1! infusion. The detailed results of infusion of both
Table 3. Effect of angiotensin 11 infusions on plasma aldosterone, cortisol and corticosterone concentrations
in anephric chronic renal failure patients
Pa- Dose Time BUN Na K "cr Hcrt Plasma Plasma Plasma Medication
tient
mg/100 ml mEq/ liter mEq/liter mg/lOOml %
aldo-
sterone
ng/lOOml
cortico-
sterone
pg/lOOm!
cortisol
pg/lOOm!
K-I Pressor 0800
1600
85 137 3.9 14.5 21.0 1.9
1.0
0.12
0.27
9.0
12.1
Coumadin, iron,
multivitamins,
heparin
K-2 Sub- 0800 48 137 4.5 10.3 24.0 8.2 0.23 9.9 Coumadin, iron,
pressor 1600 8.4 0.11 7.6 multivitamins,
heparin
D-3 Pressor 0845
1100
1300
1500
1700
36 141 4.3 8.4 26.5 5.1
3.6
4.8
2.9
2.9
0.07
0.07
0.06
0.12
0.07
10.9
6.8
7.4
11.0
6.7
Iron, multivitamins,
heparin,folate
D-4 Pressor 0800
1600
82 137 2.0 12.6 18.0 <1.0
2.5
0.07
0.10
7.0
5.6
Iron,multivitamins,
heparin, folate
D-5 Sub- 0800 94 141 2.2 15.0 20.0 1.5 0.06 7.1 Iron, multivitamins,
pressor 1600 6.2 0.06 7.0 heparin, folate
27
Supine Erect Supine Erect
Corticosterone Cortisol
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Table4. Effect of corticotropin infusion on aldosterone, cortisol and corticosterone concentrations in chronic renal failure
Pa- Kid- Time Hemo- cr Hcrt Na K Plasma Plasma Plasma Medication
tient neys dialysis
duration
aldo-
sterone
cortico-
sterone
cortisol
months mg/lOOm! % mEq/ liter mEq/liter ng/lOOml pg/lOOm! pg/lOOm!
A — 0900 1 — 27.0 136 4.2 3.8 0.42 24.2 Heparin
1300 4.8 5.37 53.0
1640 5.7 6.36 58.1
B-2 — 0900 7 6.9 24.5 144 5.1 1.0 0.25 11.3 Heparin, magalarate
1300 1.0 3.09 34.4 (Riopane), folic acid
1700 1.0 3.30 33.0
C-3 — 0900 15 — 22.0 138 5.2 1.0 1.06 21.3 Heparin, folic acid
1300 1.0 3.82 33.1
1800 1.0 4.96 39.5
D-1 — 1000 3 12.0 29.0 137 4.1 2.8 0.36 12.4 Heparin, lincomycin
1430 4.0 7.78 49.1 hydrochloride,
1730 2.9 8.52 51.1 diphenylhydantoin
0030 4.8 6.77 47.4 sodium, warfarin
0230 1.0 7.97 55.8 sodium
0800 1.0 5.10 47.0
1030 1.0 4.36 45.3
1045 1.0 4.52 47.0
E-2 + 0800 12 12,5 18.5 139 7.0 1.7 0.13 13.7 Heparin, multivita-
1700 7.1 8.29 42.0 mins, folate sodium,
iron, warfarin
sodium
F + 0800 2 7.9 19.0 147 5.1 18.5 0.82 22.4
1700 55.4 4.88 36.6
G + 0900 2 8.6 21.0 139 4.7 2.3 0.41 17.7 Heparin, diphenyl-
1700 7.6 13.5 45.4 hydantoin, multi-
vitamins, folate
H + 0900 1 — 22.0 137 4.9 1.0 0.64 14.5 Heparin, diphenyl-
1700 1.0 15.9 47.0 hydantoin sodium,
multivitamins, folate
X-2 + 0800 1 3.5 26.0 129 4.2 4.4 11.0 Heparin,multivita-
1200 3.8 27.9 mins, folate
Y-2 + 0800 1 — 33.0 136 4.6 26.0 10.5 Heparin, multivita-
1200 27.0 27.3 mins, folate
E-1 + 0800 0 12.2 24.0 138 4.0 5.2 0.14 8.9 Folate, iron
1700 21.2 7.14 43.2
I + 0800 0 6.9 21.0 143 4.3 30.7 0.58 12.5 Methyldopa, diphenyl-
1700 102.4 7.11 40.3 hydantoin, manadol,
folate
J + 0800 0 7.4 22.0 140 3.8 17.0 0.20 9.2 Hydralazine hydro-
1700 39.5 1.59 23.3 chloride (Apreso-
line), methyldopa,
diphenylhydantoin
X-1 + 0800 0 15.0 26.0 129 5.0 1.0 13.6 Multivitamins, folate,
1200 10.4 42.2 iron
Y-1 + 0800 0 14.3 16.0 146 5.8 17.0 10.4 Multivitamins, folate,
1200 58.0 43.2 iron
Z + 0800 0 12.5 23.0 143 5.9 51.0 12.7 Multivitamins, folate,
1200 134.0 32.9 iron
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subpressor and pressor doses of angiotensin II in two
anephric subjects (AN) are shown in Table 3. Heparin was
administered to all patients. Neither dose caused any
marked increase in plasma aldosterone concentration, the
biggest increment being 1.5 to 6.2 ng/100 ml at a subpres-
sor dose in subject D-5. Plasma cortisol and corticosterone
concentrations were similar in the normal range through-
out each of the studies.
Aldosterone, corticosterone and cortisol response to A CTH.
The detailed results of the sixteen studies are shown in
Table 4. In the four anephric patients (AN), ACTH in-
fusion resulted in a normal cortisol and corticosterone
response without change in the plasma aldosterone con-
centration. In one subject (D-l), the infusion was continued
for 24 hours without any rise in aldosterone concentration.
In the six patients with chronic renal failure with kidneys
receiving hemodialysis (NEH), the results were variable
(Table 4). Three had no response. In two others (E-2, G)
an increase from low concentrations to 7.1 and 7.6 ng/
100 ml was observed. In the fourth study of this group, the
preinfusion level was elevated (18.6 ng/100 ml) and, follow-
ing ACTH administration, it rose to 55.4ng/lOOml.
Plasma cortisol and corticosterone concentrations in all
subjects in this group rose to the same extent as those of
the anephric group and as those of patients with chronic
renal failure who were not receiving hemodialysis. In this
latter group (NE), plasma aldosterone concentrations rose
significantly in all six subjects following ACTH infusion.
Preinfusion levels were elevated in two of the patients.
Discussion
Volume depletion in the anephric subjects in this study
did not result in increased plasma concentrations of aldo-
sterone. This could be interpreted to mean that the kidneys
are essential for the normal aldosterone response to volume
deficiency in man. This would be in agreement with the
preliminary report of Boyd et al who found plasma aldo-
sterone concentrations of less than 2 ng/l00 ml in three
nephrectomized subjects after peritoneal dialysis had de-
pleted them of 170 to 330 mEq of sodium [21]. In contrast
to these studies, Bayard et al found that although plasma
aldosterone concentrations were low (2.6 1.2 ng/100 ml)
on the first day after hemodialysis, they rose (10.5 3.7 ng/
100 ml) as body weight increased over the next three days
[221. They concluded that this response in plasma aldo-
sterone concentration was probably due to an increase in
plasma potassium because when changes in potassium
balance were prevented, no significant increase in plasma
aldosterone was observed. In the present study, even though
the serum potassium values the day after dialysis were
sometimes high-normal or elevated, the plasma aidosterone
concentrations were still low and unresponsive to cortico-
tropin infusion or posture. A similar effect of increasing
potassium concentration on aldosterone secretion has been
observed in the hypophysectomized sheep [6]. Uremia is a
consequence of nephrectomy and it may contribute to the
effect of potassium, ACTH or serotonin on aldosterone
secretion rate in the nephrectomized animal [23]. The post-
dialysis plasma aldosterone concentrations in these studies
were low when compared with values normally found in
man [13, 18, 20, 24]. Gleadle et al also found that plasma
aldosterone concentrations in three hypertensive patients
were markedly reduced but not abolished following ne-
phrectomy [25]. In both the sheep and dog, nephrectomy
reduces the aldosterone secretion rate of the sodium-de-
pleted hypophysectomized animal to basal levels [1, 2, 4, 6],
thus establishing a role for the kidney in the control of
aldosterone secretion in these species. In the rat, nephrec-
tomy does not cause a fall in aldosterone secretion rate [11],
and sodium depletion by dialysis results in a normal aldo-
sterone tesponse [12].
The normal aldosterone response to both angiotensin II
and ACTH infusion in anephric subjects were abolished in
the present study and also in that of Boyd et al [21]. How-
ever, Melby, in an adrenal vein catheterization study,
found that angiotensin II infusion stimulated aldosterone
secretion in a single anephric patient (26], and Mitra
et al [27] found a normal aldosterone response to ACTH
in eight anephric patients maintained on peritoneal dialysis
rather than hemodialysis. In experimental studies in the
dog and sheep, the response of the nephrectomized animal
to direct stimuli of aldosterone secretion was normal, in
contrast to the findings of our present studies in man.
Twenty-four hours following nephrectomy in the sodium-
deplete sheep, when aldosterone secretion rate had fallen
to basal levels, increasing plasma potassium concentration
or angiotensin II or renin infusion resulted in an increase in
aldosterone secretion rate [6]. Similarly, it has been de-
monstrated that lowering plasma sodium concentration or
injection of angiotensin lE stimulates aldosterone secretion
in the anephric dog [28]. As might be expected, these
animals did not show an aldosterone response to hemor-
rhage because this response is thought to be mediated
through the renin-angiotensin system. In the present study
when heparin was intermittently infused in all patients, the
aldosterone response to ACTH was abolished, while cortisol
and corticosterone appeared to respond normally. Boyd
et al reported similar findings [21].
The aldosterone response to postural change was not
seen in anephric man in either this study or that of Bayard
et al [22]. Similarly, Balikian et al also failed to find an
increase in plasma aldosterone concentration after supine-
sitting postural change in an anephric man [29]. They sug-
gested that the high normal supine value (4.8 ng/100 ml)
may have been due to hyperkalemia. In contrast, in the
study by Mitra et al [27], upright posture did produce a
rise in aldosterone concentration. However, there were
several important differences between their study and the
present one. Mitra et al used no heparin in dialyzing their
subjects, and their subjects may have been stressed more
by upright activity without walking so that both a rise in
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ACTH and a fall in hepatic blood flow rate, ie, a fall in
the clearance rate of aldosterone, accounted for the rise in
plasma aldosterone concentration. That ACTH may have
been the major factor is indicated by the highly significant
positive correlation (P< 0.001; index of determination,
0.44; correlation coefficient, 0.66) between the plasma
concentrations of aldosterone and cortisol in their anephric
subjects. Neither in normal man [16] nor in our patients
did such a correlation exist with upright posture.
An explanation for the failure of the adrenal to produce
more than basal concentrations of aldosterone in nearly
all anephric subjects in the present study is not certain.
This unresponsiveness could be related to the absence of
kidneys per se. This seems unlikely since under some
circumstances in anephric man, aldosterone secretion can
be increased [22, 27]. The normal aldosterone responses to
ACTH infusion and posture changes in the subjects with
renal failure not on hemodialysis make chronic uremia an
unlikely cause for the blunted response. Because most
nephric patients lost their responsiveness when started on
hemodialysis, some change(s) produced by this procedure
would seem to be the likely cause. This is most clearly
demonstrated in the studies using ACTH. The control
plasma aldosterone concentrations were not significantly
different in the nephric patients whether or not they were
on hemodialysis; yet, the aldosterone response to ACTH
administration was significantly less (P< 0.05) in those
patients on hemodialysis. Furthermore, there were no
significant differences in the aldosterone responses to
ACTH administration in patients on hemodialysis whether
or not kidneys were present, implying hemodialysis itself
has altered the responsiveness of the adrenal gland. Since
the peritoneally dialyzed patients of Mitra et al had normal
aldosterone responses to ACTH infusion, dialysis itself
does not seems to be the cause. However, there are a
number of differences between hemodialysis and peritoneal
dialysis. First, hemodialysis is, on the whole, more efficient,
and potassium depletion is more likely to occur. The re-
sponse of aldosterone to acute stimulation has been pre-
viously shown to be markedly altered by potassium balance
with a blunted response on a low compared to high potas-
sium intake [30, 31].
Another difference between the two methods is the use
of heparin with hemodialysis. Heparin and heparinoids
are known to cause hypoaldosteronism in man when ad-
ministered for prolonged periods [32], and also to suppress
the raised aldosterone secretion rate in sodium-depleted
man [33—35]. Patients in the present study on hemodialysis
received about 300 mg of heparin each week, administered
as a 100mg infusion over 8 hours, three times weekly.
These rates of heparin administration are lower than those
shown by Bailey and Ford to inhibit aldosterone secre-
tion [33]. However, the inhibition of aldosterone secretion
may be related to the prolonged period of administration
in the anephric patients. Whatever the cause of the blunted
aldosterone response, it was effective in nearly all cases.
Only 10% of the patients on hemodialysis had elevated
basal concentrations, none of whom responsed to acute
stimulation. Furthermore, only 10% demonstrated a re-
sponse to acute stimulation, in contrast to a 90% response
rate in the chronic renal failure subjects not on hemo-
dialysis.
The present studies do not allow a precise statement to be
made as to the part the kidney plays in controlling the
aldosterone response to sodium depletion in man, and
further studies will be required to determine whether the
renin-angiotensin system plays either a permissive or a
dominant role. The data show impairment of aldosterone
secretory response to physiological stimuli under the con-
ditions of the clinical regime used, which may in part be
related to the heparin therapy or potassium depletion.
Whether this represents any handicap to these patients
during their normal daily patterns of activity is not clear.
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